API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. 3-ib-meca
2. N(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
3. N(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide
4. N(6)-ibamu
1. Piclidenoson
2. 152918-18-8
3. Cf-101
4. 3-ib-meca
5. Cf 101
6. N(6)-ibamu
7. Cf101
8. N(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
9. Piclidenoson [usan]
10. 1-deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-n-methyl-beta-d-ribofuranuronamide
11. Chembl119709
12. (2s,3s,4r,5r)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-n-methyloxolane-2-carboxamide
13. Chebi:73286
14. 30679umi0n
15. (2s,3s,4r,5r)-3,4-dihydroxy-5-(6-((3-iodobenzyl)amino)-9h-purin-9-yl)-n-methyltetrahydrofuran-2-carboxamide
16. 3-iodobenzyl-5'-n-methylcarboxamidoadenosine
17. N6-(3-iodobenzyl)adenosine-5'-n-methyluronamide
18. (2s,3s,4r,5r)-3,4-dihydroxy-5-(6-(3-iodobenzylamino)-9h-purin-9-yl)-n-methyltetrahydrofuran-2-carboxamide
19. N(6)-(3-iodo-benzyl)adenosine-5'-n-methyluronamide
20. (2s,3s,4r,5r)-5-{6-[(3-iodobenzyl)amino]-9h-purin-9-yl}-3,4-dihydroxy-n-methyltetrahydrofuran-2-carboxamide
21. N(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide
22. Unii-30679umi0n
23. Rpr-113090
24. 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-n-methyl-beta-d-ribofuranuronamide
25. Ibmeca
26. Piclidenoson (usan/inn)
27. Piclidenoson [inn]
28. Gtpl422
29. Mls002153391
30. Piclidenoson [who-dd]
31. Schembl465039
32. Regid_for_cid_123683
33. Dtxsid50165158
34. Hms2234i04
35. Hms3412e09
36. Hms3676e09
37. 3,4-dihydroxy-5-[6-(3-iodo-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic Acid Methylamide
38. Cf-101; Ib-meca; Piclidenoson
39. Ex-a2514
40. Zinc3811810
41. Bdbm50118812
42. Mfcd00671785
43. Si-615
44. Akos024456363
45. Cs-5048
46. Db05511
47. Ib-meca, Solid, >=98% (hplc)
48. Ncgc00024978-02
49. Ncgc00024978-03
50. Ncgc00024978-04
51. Ncgc00024978-05
52. Ncgc00024978-09
53. Ac-36111
54. As-16876
55. Beta-d-ribofuranuronamide, 1-deoxy-1-(6-(((3-iodophenyl)methyl)amo)-9h-purin-9-yl)-n-methyl-
56. Hy-13591
57. Smr001230772
58. D10971
59. A848868
60. J-008958
61. N6-(3-iodobenzyl)-5''-n-methylcarboxamidoadenosine
62. (n-6-(3-iodobenzyl)adenosine-5''-n-methyluronamide
63. Q27088384
64. Adenosine, N(6)-[3-iodobenzyl]-4'-methylcarbamoyl-4'-dehydroxymethyl-
65. 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-n-methyl-?-d-ribofuranuronamide
66. (2r,3r,4s,5s)-5-(6-(3-iodobenzylamino)-9h-purin-9-yl)-3,4-dihydroxy-n-methyl-tetrahydrofuran-2-carboxamide;cf 101
67. (2s,3s,4r,5r)-3,4-dihydroxy-5-[6-(3-iodo-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic Acid Methylamide
68. (2s,3s,4r,5r)-5-(6-(3-iodobenzylamino)-9h-purin-9-yl)-3,4-dihydroxy-n-methyl-tetrahydrofuran-2-carboxamide
69. (3r,4s,5r)-3,4-dihydroxy-5-[6-(3-iodo-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic Acid Methylamide
70. (3s,4r,5r)-3,4-dihydroxy-5-[6-(3-iodo-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic Acid Methylamide
71. .beta.-d-ribofuranuronamide, 1-deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-n-methyl-
72. 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-n-methyl-beta-d-ribofuranuronamide;n6-(3-iodobenzyl)adenosine-5'-n-methyluronamide;(2r,3r,4s,5s)-5-(6-(3-iodobenzylamino)-9h-purin-9-yl)-3,4-dihydroxy-n-methyl-tetrahydrofuran-2-carboxamide;cf 101
Molecular Weight | 510.3 g/mol |
---|---|
Molecular Formula | C18H19IN6O4 |
XLogP3 | 0.9 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 5 |
Exact Mass | 510.05125 g/mol |
Monoisotopic Mass | 510.05125 g/mol |
Topological Polar Surface Area | 134 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 589 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in cancer/tumors (unspecified), eye disorders/infections, psoriasis and psoriatic disorders, and rheumatoid arthritis. Can-Fite BioPharma has reported that by targeting the adenosine A3-receptor, CF101 may also be used to treat Crohn's disease, a serious gastrointestinal disorder.
CF-101 is an adenoside A3 agonist for the treatment of a variety of autoimmune-inflammatory disorders, particularly rhematoid arthritis. In clinical trials, it was found to be safe, well tolerated and showed strong evidence of an anti-inflammatory effect in rheumatoid arthritis patients. In this trial, a statistically significant correlation was found between A(3)AR expression level and response to the drug, so A(3)AR expression may serve as a biopredictor of patient response.
CF 101 is an A(3)AR agonist. A(3)AR is highly expressed in inflammatory cells and overexpressed in peripheral blood mononuclear cells, reflecting its role in the remote inflammatory process. In normal tissues, there is low adenoside A3 receptor expression. A(3)AR activation with a specific agonist deregulates the NF-kappaB signaling pathway in inflammatory cells and initiates immunomodulatory effects.